15 -0.5 (-3.23%) | 02-14 13:33 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 18.33 | 1-year : | 21.41 |
Resists | First : | 15.69 | Second : | 18.33 |
Pivot price | 12.77 ![]() |
|||
Supports | First : | 12.73 | Second : | 10.89 |
MAs | MA(5) : | 15.34 ![]() |
MA(20) : | 12.32 ![]() |
MA(100) : | 11.68 ![]() |
MA(250) : | 7.04 ![]() |
|
MACD | MACD : | 1 ![]() |
Signal : | 0.6 ![]() |
%K %D | K(14,3) : | 91.9 ![]() |
D(3) : | 94 ![]() |
RSI | RSI(14): 79.3 ![]() |
|||
52-week | High : | 15.69 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FNCH ] has closed below upper band by 19.7%. Bollinger Bands are 408.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 15.62 - 15.7 | 15.7 - 15.77 |
Low: | 14.81 - 14.9 | 14.9 - 14.98 |
Close: | 14.85 - 15.01 | 15.01 - 15.14 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Thu, 06 Feb 2025
Finch Therapeutics: Post-Trial Decision Can Potentially Drive Shares To Trade Higher - Seeking Alpha
Sat, 01 Feb 2025
5 Best Microbiome Companies (February 2025) - Securities.io
Mon, 21 Oct 2024
Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewswire
Fri, 09 Aug 2024
Finch wins US jury trial against Ferring over fecal-transplant patents - Reuters
Sat, 24 Feb 2024
Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation - TipRanks
Wed, 19 Apr 2023
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560% - Penny Stocks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 2 (M) |
Shares Float | 1 (M) |
Held by Insiders | 53.4 (%) |
Held by Institutions | 4.6 (%) |
Shares Short | 19 (K) |
Shares Short P.Month | 11 (K) |
EPS | -8.81 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 8.85 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -21.9 % |
Return on Equity (ttm) | -67.3 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -12.12 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -18 (M) |
Levered Free Cash Flow | -16 (M) |
PE Ratio | -1.71 |
PEG Ratio | 0 |
Price to Book value | 1.69 |
Price to Sales | 0 |
Price to Cash Flow | -1.34 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |